TABLE 1.

Patients characteristics and parameters at baseline, before and after starting dupilumab treatment

Parameter	Number of exacerbations		Prednisone maintenance dose (mg/day)		FEV1 %pred		Total IgE kU/L		Serum eosinophils (absolute × 109/L)
Patient sex, age	During 6 months before start dupilumab	During 6 months after start dupilumab	Base line	After 6 months	Base line	After 6 months	Base line	After 6 months	Base line	After 6 months
1. M, 83	3	0	10	0	84	103	1841	913	0.04	0.27
2. M, 78	1	0	10	2.5	92	94	4147	651	N/A	0.55
3. M, 52	3	0	10	0	95	109	994	474	0.21	0.11
4. M, 61	4	1	No stable dose	0	27	26	1046	531	0.55	N/A
5. M, 74	3	0	7.5	0	96	106	2324	N/A	1.84	N/A
6. F, 78	2	1	10	5	68	N/A	>2000	N/A	0.4	N/A
7. M, 69	1	0	7.5	5	69	88	66	N/A	0.00	0.07
8. M, 21	3	1	0	0	55	65	4598	1143	1.6	0.31